Anti-Cannabinoid Receptor-2, NT (CB2)

Cannabinoids, a group of C21 compounds present in Cannabis sativa L., their carboxylic acids, analogs, and transformation products, are the active ingredients found in hasish and marihuana. (-)-trans-D9-tetrahydrocannabinol (D9-THC) is the major psychopharmacologically active component of cannabis. Cannabis affect cognition and memory, euphoria and sedation, and antinociception (analgesia) without the respiratory depression problems associated with opioid analgesics. D9-THC is also immunosuppressive and impairs cell-mediated immunity, humoral immunity and cellular defenses against a variety of infectious agents both in vivo and in vitro. To date, two sub-types of the G-protein coupled cannabinoid receptor, CB1 and CB2, have been identified. The first brain-derived endogenous cannabinoids, an unsaturated fatty-acid ethanolamide, arachidonylethanolamide (AEA, also called anandamide) was found in brain. AEA has higher affinity for the CB1 than for the CB2. Applications: Suitable for use in Western Blot and ELISA. Other applications have not been tested. Recommended Dilution: Western Blot: 1-10ug/ml using Chemiluminescence technique. , ELISA: 1:10,000-1:100,000 using 50-100ng control peptide per well., Optimal dilutions to be determined by the researcher. Control Peptide: C1075-76A Cannabinoid Receptor 2, Human Control Peptide, NT, Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute with sterile 40-50% glycerol, PBS. Aliquot and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.